Should fluoroquinolones be first-line antibiotics in the treatment of community-acquired pneumonia in areas with high incidence of tuberculosis?

PO-REN HSUEH2020-12-182020-12-1820071684-1182https://scholars.lib.ntu.edu.tw/handle/123456789/528759[SDGs]SDG3ciprofloxacin; gemifloxacin; levofloxacin; moxifloxacin; ofloxacin; quinolone derivative; tuberculostatic agent; bacterium isolate; community acquired pneumonia; drug safety; editorial; endemic disease; human; incidence; multidrug resistance; Mycobacterium tuberculosis; outcome assessment; prevalence; primary health care; risk assessment; tuberculosis; Anti-Bacterial Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Pneumonia; Taiwan; TuberculosisShould fluoroquinolones be first-line antibiotics in the treatment of community-acquired pneumonia in areas with high incidence of tuberculosis?editorial179325962-s2.0-38049079962